Literature DB >> 3174635

Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase.

R L Coppel1, L J McNeilage, C D Surh, J Van de Water, T W Spithill, S Whittingham, M E Gershwin.   

Abstract

Primary biliary cirrhosis is a chronic, destructive autoimmune liver disease of humans. Patient sera are characterized by a high frequency (greater than 95%) of autoantibodies to a Mr 70,000 mitochondrial antigen, a component of the M2 antigen complex. We have identified a human cDNA clone encoding the complete amino acid sequence of this autoantigen. The predicted structure has significant similarity with the dihydrolipoamide acetyltransferase (EC 2.3.1.12) of the Escherichia coli pyruvate dehydrogenase multienzyme complex. The human sequence preserves the Glu-Thr-Asp-Lys-Ala motif of the lipoyl-binding site and has two potential binding sites. Expressed fragments of the cDNA react strongly with sera from patients with primary biliary cirrhosis but not with sera from patients with autoimmune chronic active hepatitis or sera from healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3174635      PMCID: PMC282177          DOI: 10.1073/pnas.85.19.7317

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis.

Authors:  P A Berg; R Klein; J Lindenborn-Fotinos; W Klöppel
Journal:  Lancet       Date:  1982-12-25       Impact factor: 79.321

2.  The pyruvate dehydrogenase complex of Escherichia coli K12. Nucleotide sequence encoding the dihydrolipoamide acetyltransferase component.

Authors:  P E Stephens; M G Darlison; H M Lewis; J R Guest
Journal:  Eur J Biochem       Date:  1983-07-01

3.  A new pair of M13 vectors for selecting either DNA strand of double-digest restriction fragments.

Authors:  J Messing; J Vieira
Journal:  Gene       Date:  1982-10       Impact factor: 3.688

4.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

5.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

Authors:  C Yanisch-Perron; J Vieira; J Messing
Journal:  Gene       Date:  1985       Impact factor: 3.688

6.  Nucleotide sequence of the sucB gene encoding the dihydrolipoamide succinyltransferase of Escherichia coli K12 and homology with the corresponding acetyltransferase.

Authors:  M E Spencer; M G Darlison; P E Stephens; I K Duckenfield; J R Guest
Journal:  Eur J Biochem       Date:  1984-06-01

7.  Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens.

Authors:  I H Frazer; I R Mackay; T W Jordan; S Whittingham; S Marzuki
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

8.  Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen.

Authors:  J Lindenborn-Fotinos; H Baum; P A Berg
Journal:  Hepatology       Date:  1985 Sep-Oct       Impact factor: 17.425

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Easy identification of cDNA clones.

Authors:  U Rüther; B Müller-Hill
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  47 in total

Review 1.  Primary biliary cirrhosis. Connecting molecular biology to clinical medicine.

Authors:  S Reynoso-Paz; R L Coppel; Y Nakanuma; M E Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Molecular biology and the diagnosis and treatment of liver diseases.

Authors:  Howard J Worman; Lin Feng; Naoto Mamiya
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

3.  B cell depletion therapy exacerbates murine primary biliary cirrhosis.

Authors:  Amy Dhirapong; Ana Lleo; Guo-Xiang Yang; Koichi Tsuneyama; Robert Dunn; Marilyn Kehry; Thomas A Packard; John C Cambier; Fu-Tong Liu; Keith Lindor; Ross L Coppel; Aftab A Ansari; M Eric Gershwin
Journal:  Hepatology       Date:  2010-12-28       Impact factor: 17.425

Review 4.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

Review 5.  Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis.

Authors:  Tin K Mao; Paul A Davis; Joseph A Odin; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 6.  Primary biliary cirrhosis: nature of autoantigens.

Authors:  M F Bassendine; S J Yeaman
Journal:  Springer Semin Immunopathol       Date:  1990

7.  Anti-M9 antibodies in sera from patients with primary biliary cirrhosis recognize an epitope of glycogen phosphorylase.

Authors:  R Klein; P A Berg
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

Review 8.  Molecular characterization of the mitochondrial autoantigens in primary biliary cirrhosis.

Authors:  P S Leung; J Van de Water; R L Coppel; M E Gershwin
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 9.  A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis.

Authors:  Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin
Journal:  Expert Rev Mol Diagn       Date:  2016-03-30       Impact factor: 5.225

10.  MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis.

Authors:  Tomohiro Katsumi; Masashi Ninomiya; Taketo Nishina; Kei Mizuno; Kyoko Tomita; Hiroaki Haga; Kazuo Okumoto; Takafumi Saito; Tooru Shimosegawa; Yoshiyuki Ueno
Journal:  Lab Invest       Date:  2016-09-26       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.